Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis

Corlan, Ana Silvia; Cîmpean, Anca Maria; Jitariu, Adriana-Andreea; Melnic, Eugen; Raica, Marius

doi:10.1155/2017/3232905

Cited by 16 publications

(7 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We are aware that our experiments, as often happens when chemotherapy side effects are investigated in experimental models, were performed in naïve animals and not in tumor-bearing mice, a condition that could in turn impact on the emotional component. Interestingly, PKs have been shown to have a role in tumor progression inducing angiogenesis and sustaining inflammation [ 58 , 59 ]. In particular, PK1 or EG-VEGF is important in the neo vascularization process and is involved in multiple myeloma cells proliferation and survival [ 60 ] while PK2 is a recognized proinflammatory cytokine [ 58 ].…”

Section: Discussionmentioning

confidence: 99%

The Antagonism of the Prokineticin System Counteracts Bortezomib Induced Side Effects: Focus on Mood Alterations

Amodeo

Verduci

Sartori

et al. 2021

IJMS

View full text Add to dashboard Cite

The development of neuropathy and of mood alterations is frequent after chemotherapy. These complications, independent from the antitumoral mechanism, are interconnected due to an overlapping in their processing pathways and a common neuroinflammatory condition. This study aims to verify whether in mice the treatment with the proteasome inhibitor bortezomib (BTZ), at a protocol capable of inducing painful neuropathy, is associated with anxiety, depression and supraspinal neuroinflammation. We also verify if the therapeutic treatment with the antagonist of the prokineticin (PK) system PC1, which is known to contrast pain and neuroinflammation, can prevent mood alterations. Mice were treated with BTZ (0.4 mg/kg three times/week for 4 weeks); mechanical allodynia and locomotor activity were evaluated over time while anxiety (dark light and marble burying test), depression (sucrose preference and swimming test) and supraspinal neuroinflammation were checked at the end of the protocol. BTZ treated neuropathic mice develop anxiety and depression. The presence of mood alterations is related to the presence of neuroinflammation and PK system activation in prefrontal cortex, hippocampus and hypothalamus with high levels of PK2 and PKR2 receptor, IL-6 and TNF-α, TLR4 and an upregulation of glial markers. PC1 treatment, counteracting pain, prevented the development of supraspinal inflammation and depression-like behavior in BTZ mice.

show abstract

Section: Discussionmentioning

confidence: 99%

The Antagonism of the Prokineticin System Counteracts Bortezomib Induced Side Effects: Focus on Mood Alterations

Amodeo

Verduci

Sartori

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Other known members include VEGF-E (virus source), VEGF-F (snake venom source) and EG-VEGF (endocrine gland-derived vascular endothelial growth factor). In addition, there are 3 VEGF receptors, VEGFR1 (Vascular Endothelial Growth Factor Receptor 1-FLT1 gene) and VEGFR2 (KDR gene), mainly expressed in VECs (vascular endothelial cell), and VEGFR3 (FLT4 gene), which is primarily expressed in LECs (lymphatic endothelial cells) [2,3]. With the regulation of lipid metabolism through the involvement of the lymphatic system in one-way absorption and transport of lipids from the gastrointestinal tract to the venous system [4].…”

Section: Introductionmentioning

confidence: 99%

The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets

Dabravolski

Khotina

Omelchenko

et al. 2022

IJMS

View full text Add to dashboard Cite

The vascular endothelial growth factor (VEGF) family, the crucial regulator of angiogenesis, lymphangiogenesis, lipid metabolism and inflammation, is involved in the development of atherosclerosis and further CVDs (cardiovascular diseases). This review discusses the general regulation and functions of VEGFs, their role in lipid metabolism and atherosclerosis development and progression. These functions present the great potential of applying the VEGF family as a target in the treatment of atherosclerosis and related CVDs. In addition, we discuss several modern anti-atherosclerosis VEGFs-targeted experimental procedures, drugs and natural compounds, which could significantly improve the efficiency of atherosclerosis and related CVDs’ treatment.

show abstract

“…EG-VEGF may stimulate the phosphorylation of the receptor for EGF and its activation, thus having an antiapoptotic role and stimulating the survival of tumor cells. 15 In pituitary adenomas with papillary growth pattern, we identified a correlation between the expression of EG-VEGF and PRL. It is well known that EG-VEGF and PRL have mitogenic role upon cells expressing their receptors.…”

Section: Discussionmentioning

confidence: 81%

“…3 In the normal pituitary gland, we identified the expression of EG-VEGF in acidophilic and chromophobe cells, but not in basophil cells. Previous papers reported an EGVEGF overexpression in several malignant tumors, arising from the gastrointestinal tract, 15 pancreas, 16 ovaries, 7 or colon. 17 In these tumors, EG-VEGF has an important role in tumor angiogenesis, controlling the tumor invasion and metastasis, but also the rate of proliferation of malignant cells.…”

Section: Discussionmentioning

confidence: 98%

VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas

et al. 2019

Self Cite

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF), its inhibitory splice variant, VEGF165b and Endocrine Gland derived VEGF (EG-VEGF) have a controversial role in pituitary gland. We aim to study VEGF, VEGF165b and EG-VEGF expression in pituitary adenomas. A significant correlation was found between growth hormone (GH) and VEGF secretion (P=0.024). For prolactinomas, VEGF and prolactin expression, had a P-value of 0.02 for Kendall coefficient and a P-value of 0.043 for the Spearman coefficient. VEGF-mRNA amplification was detected in both tumor cells and folliculostellate cells. VEGF165b was positive in 16.66% of pituitary adenomas. EG-VEGF was significantly correlated with prolactin (P=0.025) and luteinizing hormone (P=0.028). Our data strongly support VEGF, VEGF165b and EG-VEGF as important players of pituitary adenomas tumorigenesis. Particular hormonal milieu heterogeneity, special vascular network with an unusual reactivity to tumor growth correlated with variability of VEGF, VEGF165b and EG-VEGF secretion may stratify pituitary adenomas in several molecular groups with a direct impact on therapy and prognosis.

show abstract

Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis

Cited by 16 publications

References 104 publications

The Antagonism of the Prokineticin System Counteracts Bortezomib Induced Side Effects: Focus on Mood Alterations

The Antagonism of the Prokineticin System Counteracts Bortezomib Induced Side Effects: Focus on Mood Alterations

The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets

VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas

Contact Info

Product

Resources

About